TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05971680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VITAMIN B1 500mg
Description: VITAMIN B1 (High Potency) 500mg tab every day for 3 months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-uterine contraceptive device
Description: intra-uterine contraceptive device

Intervention type: DEVICE
Group type: OTHER
Intervention: intra-uterine contraceptive device
Description: intra-uterine contraceptive device
Study: NCT05264870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: treatment of postspinal hypotension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: treatment of postspinal hypotension
Study: NCT05081024

Intervention type: PROCEDURE
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and/or tissue samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study: NCT05578235

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapled side-to-side anastomosis
Description: Standard procedure for CD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Handsewn anastomosis
Description: handsewn end-to-end or Kono-s anastomosis
Study: NCT05081999

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Assessment
Description: medical hx, events inquiry, adherence to treatment arm periodically over 4 years

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Assessment
Description: medical hx, events inquiry, adherence to treatment arm periodically over 4 years
Study: NCT06502197

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silastic Stenting
Description: Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silastic Stenting
Description: Drill-out frontal sinus procedures, are a well-established surgical intervention in the management of CRS, involves extensive sinus surgery with the creation of a large, surgically exposed area of raw bone. This raw bone, left exposed postoperatively, poses a unique challenge in the context of mucosal healing. Silastic stents, inserted into the sinus cavities, offer a promising solution by providing structural support and facilitating mucosal re-mucolisation in this critical period of postoperative recovery.
Study: NCT05081999

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Assessment
Description: online questionnaires periodically over 4 years, including SAQ, EQ-5D-5L, IIEF-5 (males) or FSFI (females)
Study: NCT05048706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser lithotripsy (SP TLF)
Description: Laser lithotripsy of urinary calculi using the Super Pulse Thulium fiber laser (SP TLF)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser lithotripsy (Ho:YAG)
Description: Laser lithotripsy of urinary calculi using the standard Holmium: Yttrium-Aluminium-Garnet (Ho:YAG) laser.
Study: NCT06390254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience-Enhancing Nursing Suppor
Description: The resilience-building nursing intervention in this study is a multifaceted approach aimed at enhancing the psychological well-being and coping abilities of community-dwelling older adults. Unlike standard care, which typically focuses on symptom management, this intervention emphasizes proactive strategies to promote resilience and improve overall quality of life.
Study: NCT04764409

Intervention type: PROCEDURE
Intervention: Chemoembolization
Description: Transarterial Chemoembolization (TACE)

Intervention type: PROCEDURE
Intervention: Chemoinfusion
Description: Transarterial Infusion (TAI)
Study: NCT06216158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
Study: NCT05754229

Intervention type: DEVICE
Group type: OTHER
Intervention: AI-assisted colonoscopy
Description: The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
Study: NCT04960319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Lithotripsy
Description: Coronary Angiography. When the anatomic inclusion criteria are met, traverse the lesion with a guidewire. If traversal fails, assign the subject to the registry. After wire traversal has been documented by cine angiography, angiographic, OCT-defined or balloon expansion criteria are met, subject is enrolled. Blood sample for Troponin (hs TnT) baseline measurement has to be taken. The subjects will be randomized in a 1:1 fashion to treatment with either IVL or RA.
Study: NCT04754334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801
Description: Oral Insulin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fish Oil
Study: NCT06216158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone p.o. or i.v. (20 mg, cycle 1 only: day 1, 8, 15, 22)
Study: NCT06358287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryogenic auriculotherapy
Description: Compressed nitrogen is used to create a 'cryonic needle', using a cryopunctor device. An orifice is placed in appropriate acupoint and nitrogen flow is used to cool and activate the point.
Study: NCT04132401

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: algorithm
Description: The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: algorithm
Description: The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
Study: NCT05886478

Intervention type: DRUG
Intervention: No intervention
Description: As this is an observational study, no intervention will be administered.
Study: NCT04934683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine blood pressure control
Description: Routine blood pressure control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine blood pressure control
Description: Routine blood pressure control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tight blood pressure control
Description: Tight blood pressure control.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tight blood pressure control
Description: Tight blood pressure control.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Anesthetic induction with etomidate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Description: Anesthetic induction with etomidate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthetic induction with propofol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthetic induction with propofol.
Study: NCT05337774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PI-2620
Description: The participant will be injected with 5 mCi (185 MBq) \[18F\]PI-2620 via a short line which will be placed in an intravenous line in an antecubital vein. Subjects will be placed in the scanner after injection and dynamic scans will be acquired for 0 to 60 minutes post injection.
Study: NCT06645795

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training plus conventional physical therapy
Description: Participants will complete 8 weeks of intervention of robot assisted gait training with the ATLAS 2030 exoskeleton (Marsi Bionics) owned by the school which they attend to. They will have 2 weekly sessions (16 sessions in total) for 4 weeks. Each session will last up to 1 hour (depending on the child's tolerance) although a minimum of 30 minutes per session and a minimum of 12 sessions will be set in this time. The training mode will be automatic. In addition, they will continue to carry out the rest of their usual treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional pjysical therapy
Description: Participants will complete 8 weeks of conventional therapy, with 2 sessions per week (16 sessions total). During the conventional treatment period, participants will continue with the conventional physical therapy they have received thus far. The content of the usual care treatment does not specifically address gait training, but consists of elements addressing range of motion, tone reduction, balance, activities of daily living, etc. The conventional intervention may be different for each individual based on their needs (to represent usual care), however, participants will be advised not to change the intervention, type, and frequency during the study.
Study: NCT05587335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREP
Description: Relationship intervention to improve communication and conflict resolution for couples

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurRelationship
Description: Relationship intervention to improve communication and conflict resolution for couples
Study: NCT06213714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 5G Tele-Robotic-Assisted PCI
Description: The 5G Tele-Robotic-Assisted VRS100 system is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
Study: NCT05622292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HARKIT I-Care Application
Description: HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
Study: NCT06176209

Intervention type: DIAGNOSTIC_TEST
Intervention: screening tool with biomarkers for prediction of chronic post traumatic neck pain
Description: Diagnostic screening with biomarkers for prediction of chronic post traumatic neck pain
Study: NCT04814914

Intervention type: OTHER
Intervention: KB109 + Self Supportive Care
Description: KB109 is a novel glycan

Intervention type: OTHER
Intervention: Self Supportive Care (SSC) Alone
Description: Self Supportive Care (SSC) Alone
Study: NCT06571344

Intervention type: DRUG
Intervention: Cholecalciferol
Description: The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.

Intervention type: DRUG
Intervention: Cholecalciferol
Description: The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.

Intervention type: DRUG
Intervention: Cholecalciferol
Description: The patients with vitamin D (25(OH)D) levels \< 30 ng/mL, and 30-50 ng/ml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).~In the patients with 25(OH)D levels 50-80 ng/mL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.
Study: NCT05117996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Description: capsule endoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: capsule endoscopy
Description: capsule endoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard small bowel preparation
Description: 2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified small bowel preparation
Description: Liquid diet the evening before and water on the morning of the capsule endoscopy. 2 mL of Babyspasmyl after ingestion of capsule
Study: NCT05895994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study: NCT04640259

Intervention type: OTHER
Intervention: Online Survey
Description: Epidemiological Survey (approx 200 questions)

Intervention type: OTHER
Intervention: Online Survey
Description: Epidemiological Survey (approx 200 questions)

Intervention type: OTHER
Intervention: Online Survey
Description: Epidemiological Survey (approx 200 questions)

Intervention type: OTHER
Intervention: Online Survey
Description: Epidemiological Survey (approx 200 questions)

Intervention type: OTHER
Intervention: Online Survey
Description: Epidemiological Survey (approx 200 questions)
Study: NCT05384210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: Milnacipran will be administered according to the treatment recommendations for fibromyalgia, starting with 50 mg once daily for 1 week then increasing to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Patients will receive gabapentin (1200 mg twice daily) as a monotherapy. Gabapentin will be administered according to the treatment recommendations for FM patients starting with 400 mg 3 times per day, then increasing the dose to 800 mg 3 times per day with a maximum dose of 2400 mg per day according to efficacy and tolerability for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined gabapentin/milnacipran
Description: Patients will receive combined gabapentin as group B and MLN as group A
Study: NCT05076799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 ml lactulose combined with 1 L PEG
Description: the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 ml lactulose combined with 2 L PEG
Description: the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ml lactulose
Description: the participants were instructed to consume 200 ml lactulose alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 L Polyethylene glycol solution
Description: the participants were instructed to consume 3000 mL of PEG solution
Study: NCT05233007

Intervention type: PROCEDURE
Intervention: Minor endoscopic biopsy
Description: As per standard of care
Study: NCT05302570

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Proton Beam Therapy
Description: 5 fractions of 5 Gy of PBT to clinical tumor volume +/- an additional simultaneous 1 Gy per fraction to any pre-determined at-risk margin (for a total of 6 Gy per fraction x 5 fractions for at-risk margins as a simultaneous integrated boost (SIB)).
Study: NCT05009966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYSA1801 for injection
Description: SYSA1801 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT06359860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1898 tablets
Description: Supplied as 5 mg and 40 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-1898 tablets
Description: Supplied as 5 mg and 40 mg tablets
Study: NCT04158349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 0 (85 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRI
Description: mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
Study: NCT05489471

Intervention type: OTHER
Intervention: Artificial intelligence review
Description: The AI looks for ten different abnormalities on each chest X-ray and produces a heat map and percentage confidence score if it detects an abnormality.
Study: NCT05955391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-326
Description: Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles
Study: NCT05081570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telecare consultation
Description: Two tertiary stroke care consultations will be provided by stroke nurses via telecare in 2 months. Consultation content includes provide education on modifying stroke-specific risk factors, disseminate self-management knowledge, reinforce the importance of medication compliance, revise the blood and investigation results, and co-design and follow-up on mutually agreed rehabilitation goals with the subjects. When necessary, the nurse will also refer the stroke survivors to multidisciplinary team members according to the referral guidelines. The nurse will also encourage the patients' family and/or informal caregivers to participate in the consultations.
Study: NCT06187246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-based intervention
Description: Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.~It was delivered via a metaverse: Second Life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individual informative talks
Description: Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
Study: NCT03771612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Half of the participants will be randomly assigned to receive a placebo pill twice daily